Wall Street Piles Into UnitedHealth: Argus Upgrades to Buy as Three More Firms Raise Targets After Q1 Crushes Expectations

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) just earned a strong endorsement from four Wall Street firms following a better-than-expected Q1 2026 earnings report. Argus stepped up with the most significant action, upgrading UnitedHealth stock to Buy from Hold with a $400 price target, while three other firms raised their targets. For long-term investors watching this turnaround story, a rating change carries more signal than a target tweak.

If you’ve been following today’s price action, UnitedHealth Surges 8%, Humana Gains 4% as Earnings Strength Eases Medicare Advantage Concerns covers the sector-wide move. Here, we’re focused on what four analyst firms are saying and why their divergence on price targets matters.

The Analysts’ Case

Argus says UnitedHealth reported a “strong” Q1 as it pursues higher margins in its insurance lines, and the firm believes UnitedHealth is implementing disciplined pricing and exiting unprofitable Medicare Advantage markets. Argus isn’t just raising a number; it’s changing its fundamental view of the company’s trajectory.

Morgan Stanley analyst Erin Wright raised her UNH stock price target to $395 from $375, arguing that with upside on key performance indicators and a “surprise” FY26 EPS guidance raise, UnitedHealth “showcased that its turnaround is underway.” That’s a confident statement from one of Wall Street’s most-watched healthcare analysts.

Oppenheimer lifted its UNH stock price target to $405 from $385, the highest of the four, noting that early 2026 trends in all segments, including Medicare Advantage and OptumHealth, were better than expectations. BofA took the most measured tone, raising its target to $371 from $337 while keeping a Neutral rating, calling guidance “conservative” on a 50-cent EPS raise after a 70-cent EPS beat and saying it’s awaiting further visibility on Stars ratings and the 2028 Medicare Advantage rate notice.

Company Snapshot

UnitedHealth operates two core businesses: UnitedHealthcare, serving approximately 49.1 million medical members, and Optum, which spans value-based care delivery, health analytics, and pharmacy services. Q1 2026 revenue came in at $111.72 billion, beating the $109.66 billion consensus estimate, with an adjusted EPS of $7.23 versus the $6.61 estimate.

The medical cost ratio, a critical profitability measure for insurers, improved 90 basis points to 84%, signaling that UnitedHealth’s repricing efforts are gaining traction. Management raised full-year 2026 adjusted EPS guidance to greater than $18.25 per share.

Why the Move Matters Now

The UNH stock price target range across the four firms spans $371 (BofA) to $405 (Oppenheimer), which tells a clear story: even the most cautious sees meaningful room to run from here. The Argus upgrade carries the most weight because rating changes reflect a fundamental reassessment, not just a model tweak.

What It Means for Your Portfolio

Four firms moving in the same bullish direction on the same day is a signal worth noting. Granted, BofA’s Neutral flag reminds us that regulatory visibility, particularly around Medicare Advantage Stars ratings, remains an open question that could affect the pace of recovery.

For income-focused, long-term investors, UnitedHealth’s $8.9 billion in Q1 operating cash flow and committed $2 billion share buyback through Q2 reinforce the financial foundation. The turnaround narrative is gaining Wall Street backing, but watch the Medicare Advantage membership trend and Stars ratings before treating this as a largely de-risked story.